ABT-510
- Generic Name
- ABT-510
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H83N13O11
- CAS Number
- 251579-55-2
- Unique Ingredient Identifier
- CRR8E37XOB
- Background
ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
- Indication
Investigated for use/treatment in lymphoma (unspecified), melanoma, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
ABT-510 in Treating Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 42
- Registration Number
- NCT00602199
Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00113334
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath